

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Inavolisib with palbociclib and fulvestrant for treating hormone receptorpositive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after adjuvant endocrine treatment ID6425

Final Stakeholder List

Consultees	Commentators (no right to submit or
Oursuitees	appeal)
	appeary
Company	General
Roche (inavolisib)	All Wales Therapeutics and Toxicology
(,	Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality	Board of Community Health Councils in
Breast Cancer Now	Wales
Breast Cancer UK	British National Formulary
Cancer Black Care	Care Quality Commission
Helen Rollason Cancer Charity	Department of Health - Northern Ireland
Independent Cancer Patients Voice	Healthcare Improvement Scotland
 Inflammatory Breast Cancer (IBC) 	Medicines and Healthcare products
Network UK	Regulatory Agency
 Lobular Breast Cancer UK 	 National Association of Primary Care
Macmillan Cancer Support	 National Pharmacy Association
Maggie's Centres	NHS Confederation
Make 2nds Count	Scottish Medicines Consortium
Marie Curie	Welsh Government
MET UP UK	Welsh Health Specialised Services
Prevent Breast Cancer	Committee
South Asian Health Foundation	
Specialised Healthcare Alliance	Possible comparator companies
Tenovus Cancer Care	•
	AstraZeneca (fulvestrant)
Healthcare professional groups	Dr. Reddy's Laboratories (fulvestrant)
Association of Breast Surgery	Eli Lilly (abemaciclib)
Association of Cancer Physicians	Genus Pharmaceuticals (fulvestrant)
British Geriatrics Society	Medical Valley Invest AB (fulvestrant)
British Institute of Radiology	Novartis (ribociclib)
British Oncology Pharmacy	Pfizer (palbociclib)
Association	Ranbaxy (fulvestrant)
British Psychosocial Oncology Society	Sandoz (fulvestrant)
British Society of Interventional	Sun Pharmaceutical Industries Europe
Radiology	B.V. (fulvestrant)

Final stakeholder list for the evaluation of inavolisib with palbociclib and fulvestrant for treating hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after adjuvant endocrine treatment ID6425 Issue date: April 2025



Consultees	Commentators (no right to submit or appeal)
 Cancer Research UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Breast Cancer Group UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Teva UK (fulvestrant) Zentiva (fulvestrant) Relevant research groups Against Breast Cancer Breast Cancer Hope Cochrane Breast Cancer Group Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Pro-Cancer Research Fund
Others Department of Health and Social Care NHS England	 Associated Public Health groups Public Health Wales UK Health Security Agency Evidence Review Group

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of inavolisib with palbociclib and fulvestrant for treating hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after adjuvant endocrine treatment ID6425



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.